Version 2.77

Term Description

This panel contains genotype results for warfarin dosing. As of 2019, CYP2C9, VKORC1, CYP4F2, and rs12777823 genotypes are used when available to help determine a patient's initial therapeutic warfarin dose. VKORC1 and CYP2C9 genotypes are the most important genetic determinants of warfarin dosing. Additionally, a genetic variation in the CYP4F2 gene, CYP4F2*3, as well as a variant near the CYP2C gene cluster, rs12777823, have been associated with influencing warfarin therapy.[NCBI Books: NBK84174] This panel is based on, but not limited in use to, the 2017 Update of the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing, which provides warfarin dosing recommendations for adults with and without African ancestry, and also for pediatric patients.[https://cpicpgx.org/content/guideline/publication/warfarin/2017/warfarin.pdf]
Source: Regenstrief LOINC

Panel Hierarchy

Details for each LOINC in Panel LHC-Forms

LOINC Name R/O/C Cardinality Example UCUM Units
93196-4 Warfarin response genotype panel - Blood or Tissue by Molecular genetics method
Indent46724-1 CYP2C9 gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal
Indent79716-7 CYP2C9 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method
Indent50722-8 VKORC1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
Indent72507-7 VKORC1 gene c.1173C>T [Presence] in Blood or Tissue by Molecular genetics method
Indent93198-0 10q23 g.94645745G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal
Indent93197-2 CYP4F2 gene c.1297G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal
Indent79721-7 CYP4F2 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method

Fully-Specified Name

Component
Warfarin response genotype panel
Property
-
Time
Pt
System
Bld/Tiss
Scale
-
Method
Molgen

Additional Names

Short Name
Warfarin genotype pnl Bld/T
Display Name
Warfarin response genotype panel Molgen (Bld/Tiss)
Consumer Name Alpha Get Info
Warfarin response genotype panel, Blood or tissue specimen

Basic Attributes

Class
PANEL.MOLPATH.PHARMG
Type
Laboratory
First Released
Version 2.67
Last Updated
Version 2.67
Order vs. Observation
Order
Panel Type
Panel

Language Variants Get Info

Tag Language Translation
es-ES Spanish (Spain) Panel de genotipo de respuesta a warfarina:Propiedades mixtas (sólo paneles):Punto temporal:Sangre o tejido:-:Genética molecular
es-MX Spanish (Mexico) Panel de genotipo de respuesta a warfarina:-:Punto temporal:Sangre o tejido:-:Genética molecular
fr-FR French (France) Warfarine génotype panel:-:Ponctuel:Sang/Tissu:-:Biologie moléculaire
it-IT Italian (Italy) Warfarina, panel genotipo di risposta:-:Pt:Sangue/Tess:-:Molgen
Synonyms: Farmacogenomica Genetica molecolare Panel farmacogenomica Panel warfarina genotipo di risposta Patologia molecolare Punto nel tempo (episodio) Sangue Sangue o Tessuto Set di prescrizione patologia molecolare Tessuto & Strisci
zh-CN Chinese (China) 华法林反应基因型组套:-:时间点:全血/组织:-:分子遗传学类实验室方法
Synonyms: 全血或组织;血液/组织;血液或组织 分子病理学;分子病理学试验 分子遗传学;分子遗传学方法;分子遗传学类方法;分子遗传学类检验方法;包括 RFL、PCR 及其他方法在内，用于在分子基础上检测遗传属性的方法的大类;聚合酶链反应;聚合酶链式反应 医嘱套餐 医嘱套餐类 医嘱套餐组 医嘱组 医嘱组.分子病理学;分子病理学组套（组合、医嘱组、套餐、套餐医嘱、医嘱套餐、组合申请、组合项目）.药物基因组学（药物基因体学、药物基因学、药物基因组）;分子病理学医嘱组类;医嘱组类.分子病理学;实验室医嘱组类.分子病理学 医嘱组.分子病理学;分子病理学组套（组合、医嘱组、套餐、套餐医嘱、医嘱套餐、组合申请、组合项目）;分子病理学医嘱组类;医嘱组类.分子病理学;实验室医嘱组类.分子病理学 医嘱组合 医嘱组合类 医嘱组套 医嘱组套类 医嘱组类 华法令;华法林;抗血凝性杀鼠剂;杀鼠灵;灭鼠灵 华法林（苄丙酮香豆素钠、杀鼠灵、华法林抗凝血剂、华法令）反应（反应性）组套（组合、医嘱组、套餐、套餐医嘱、医嘱套餐、组合申请、组合项目） 多重;多重型;多重标尺类型;多重精度类型 套餐 套餐医嘱 套餐医嘱组 套餐医嘱组类 实验室医嘱套餐 实验室医嘱套餐类 实验室医嘱组 实验室医嘱组合类 实验室医嘱组套 实验室医嘱组套类 实验室套餐医嘱组 实验室套餐医嘱组类 实验室检验项目医嘱组合类 实验室检验项目组合类 时刻;随机;随意;瞬间 未作说明的组织;组织;组织 & 涂片 检验医嘱组合类 检验项目医嘱组合类 检验项目组合类 组 组合 组合医嘱 组合类 组套 血;血液

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=93196-4
Questionnaire definition
https://fhir.loinc.org/Questionnaire/?url=http://loinc.org/q/93196-4